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Meeting Report
In itro Teratology
by B. A. Schwetz,* R. E. Morrissey,t F. WeIsch,l and
R. A. Kaviocki
The purposeofthis conference wasto reevaluatethe needfor anduseofU vintteratolog assays; toe amine thevalidation
prcess for in tests; and progr in validaionofi teratogy screens. Participants
supported further development of short-term in Wivo and in vitm systems both as prescreens for developmental toxicity
and asexperimental systemstoexplore mcan ofactionoftoxiats. The group stronglyendorsedthedevelopment
ofanupdatedreferencelist ("goldstandard")ofknowndevelopmentaltoxicantsandnontoxicants asessential tofurther
progressindevelopingandvalidatingprescreeningefforts. Independently, anexpert groupshouldfurtherevaluatethe
performancecharacteristicsfor avalidated prescreen. Thelimitsofusefulness ofprescreensforproductdevelopment,
regulatory use, andmechanistic investigations needtobe clearly defined. Fnally, toofewin vitro teratology prescreens
havebeenevaluatedundermultiple-laboratory conditionswith common,agreed-upon testagents todrawfirmconclu-
sionsregardingthemeritandreproducibility ofin vitro teratoogy prescreens. There wasgeneral agreementregarding
theneedtomovesevenlofthe asaysfurtheralongthevalidationpathway,atleastusin ashortlistofreferencecmnounds.
Introduction
In the early 1980s, there was considerable optimism that in
vitro assays (e.g., theAmestest)wouldprovidevaluableinsights
into the potential for compounds to produce toxicity. Further-
more, the Toxic Substances Control Act requirements for tox-
icological data placed an additional testing responsibility on
manufacturers, and it appeared that in vitro toxicology assays
might proveuseful inprescreening compounds forprioritization
foradditional, in-depthtesting. It wasappropriate, therefore, that
aConsensusWorkshop onIn VitroTeratogenesisTesting(1) was
held in 1981 to discuss in vitro teratology assays and how they
couldfitintotoxicity screening andregulatory riskassessment.
Validation ofin vitro teratology prescreens was considered of
highpriority because oftheneed tocharacterize thetoxicity of
large numbers ofuntestedchemicals andthe resultant need for
prioritization ofchemicals as well asthe stimulus to focus our
animal and laboratory resources to needs ofhighest priority.
Thus, the earlier workshop was held to review the status ofin
vitro prescreensandalsotodevelop alistofreferencechemicals
forfurthervalidationefforts. TheNationalToxicologyProgram
established arepositoryofthosechemicals onthereferencelist.
Duringtheinterveningdecade, considerable progresshasbeen
madetowarddevelopmentandvalidation ofnew prescreens for
developmental toxicity. A conference was held atthe National
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1989, toreviewthatprogress,whichissummarizedinthispaper.
Thepurposeofthemeetingwastoreevaluatetheneedforanduse
ofin vitroteratologyassays, toexaminethevalidationprocessfor
invitrotests, andtodiscussprogressinthevalidationofin vitro
teratology screens. The conference was attended by about 100
peoplerepresenting abroadspectrumofinterestsfromuniver-
sity, government, industry, andcontractlaboratoryperspectives.
Speakersandtopicsaddressedaresummarized inTable 1. Points
of agreement or disagreement that surfaced as important
thoughts from the meeting are summarized in the following
sections.
Topics of Discussion
DefinitionsofTermsandClarificationofConcepts
In vitro teratology assays have adual purpose, being used in
bothmechanisticandscreeningstudies. Theprimary focusofthe
discussions atthis conference was onthepredictiveness ofthe
assays for the outcome ofSegment II teratology studies as re-
quiredby regulatory agencies.
Therewasconsiderablediscussionaroundthetopicofseman-
tics. Therewasnoagreement, forexample, onthedefinitionsof
prescreen, screen, anddefinitive studies. Someparticipantsfelt
that Segment H animal studies, often referred to as teratology
studies, arescreens forpotentialadverseeffects inhumansand
thatany in vitroassay conducted in aninitial assessmentmode
shouldbeconsideredaprescreen. Othersobservedthateffects
inhumansaredifficulttodetermine, andSegmentIIdatamaybe
as definitive a set ofdevelopmental toxicity data as would be
available; thus, an in vitro assay would be a screen for these
effects. The term "prescreen" will be used here for any assay
usedtopredicttheoutcomeofSegmentII studies. ParticipantsSCHWE7ZETAL.
Table 1. Topicsandspeakersforcurrentdevelopments ininvitroteratology
workshop andconference.
Topic Speaker
In vitro tests and their uses
Historical perspective-1981 Little Rock Conference K. Smith
Overview ofin vitro teratology tests and obstacles to F. Welsch
their use
In vitro tests: uses and needs
Screening decisions 0. Flint
Mechanistic understanding T. Sadler
Regulatory decisions G. Kimmel
The validation process
What is validation? R. Scala
Experiences from genetic toxicology validation M. Shelby
studies
Reference list: test strategy progress update R. Morrissey
Developmental toxicity graphical data profiles R. Kavlock
Progress update-in vitro teratology test systems
Micromass 0. Flint
Chick retina G. Daston
Mouse ovarian tumor and human palate cell assays' R. Morrissey
Hydra M. Johnson
Drosophila D. Lynch and
R. Schuler
FETAX J. Bantle
Whole embryo culture-mechanisms A. Fantel
Whole embryo culture-prescreens B. Schmidt
aOnly two assays that have beenindependently evaluated.
agreedthatdevelopmental toxicity includes structural malforma-
tions, embryonic orfetaldeath, decrements infetalbodyweight,
and functional deficits following birth. However, there was no
consensus as tohow many orwhich ofthesetypesofadverseef-
fects a prescreen mustpredict tobeuseful. Itis recognizedthat
the term "teratology" is often used interchangeably with "de-
velopmentaltoxicity," especially as itrelates toin vitrostudies.
Furthermore, there was noagreementreachedconcerningwhat
constitutes a "positive" or"negative" responseinanimalstudies,
although there are generally agreed-upon working criteria,
which includethe presenceofastatistically significantdifference
from control values, the presence of a dose-response relation-
ship, and a number ofexperimental design considerations in-
cluding thenumberofanimals, thedoseselection, thegestational
daysoftreatment, the useofproperstatistics, andfreedom from
significant confounders. Thus, as for in vivodata, the grouprein-
forced the importance ofestablished criteriaby which theinter-
pretation ofin vitro tests will be determined.
Usefulness ofPrescreens
There were several points of agreement concerning in vitro
assays: a)Testsgivevaryingdegreesofinformationaboutthesite
andmodeofactionofchemicalsbased onthelevelofbiological
organization and the design ofthe prescreen. Single end point
prescreens give aspecific answeraboutthatendpointand pro-
bablylittlemore. Suchscreens maygiveveryusefulinformation
aboutstructure-activity relationshipswithinachemicalgroup,but
havelimitedpotentialforusewithawidevarietyofchemicalstruc-
tures. Incontrast, wholeorganisms screenformorecriticalevents
(and thus are more likely to be useful for a wide variety of
chemicals)butprovidelessspecificinformationaboutthesiteand
mechanismofactioncomparedto asingleendpointprescreen.
b)Whilethe specific usesofprescreens vary from onelabor-
atory to another, there was agreement that prescreens have
potentialusesofconsiderableimportancebeyondstudiesofthe
mechanismofaction. Thestrongestendorsementcamefromthe
use of an assay to discriminate between varying degrees of
biological activity of members of a class of chemicals when
groups ofchemicals needed to be prioritized in rank order of
potential toxicity.
c) Several prescreens predict the outcome of Segment II or
similarstudieswithanaccuracyintherangeof60to85%. This
compares with the concordance ofrat, mouse, and rabbit Seg-
mentIIstudieswithhumandataof70, 70, and50%, respectively
(2). Nosingleprescreenshows 100% concordancewiththeout-
comeofthesedevelopmental toxicitystudies. Whiledifferentin-
vestigators involved in validation ofprescreens have used dif-
ferentlistsofreferencecompounds, itisclearthatnoneofthelists
werebasedonlyonSegmentIIdata. Infact, SegmentII studies
have notbeen done for several recognized humanteratogens.
d) Since several prescreens are reasonably predictive ofthe
outcomeofSegmentIIstudies, thefieldwouldprobablybenefit
morefromfurtherrefinementandevaluationofthemostpromis-
ingprescreensratherthanextensivesearchingfornewerandbet-
terassays. Certain systems thatwere shelved forone reason or
another, such as the chick embryo test, should perhaps be re-
reviewed to evaluate theirpotential usefulness.
e) Someparticipants feltthatin vitro assays may beuseful in
special situations in which, for example, quantities ofa com-
poundorametabolite are very limited or in studying mixtures
ofcompounds.
Performance Characteristics ofPrescreens
Noneoftheprescreenswereconsideredtobefullyvalidated.
Onlythemouseovariantumorcellandhumanembryonicpalatal
mesenchymalcellassayshavebeenevaluatedinindependentin-
terlaboratory studies; thus, the level of concordance of pre-
screens with in vivodata cannotbe assessed atthis time.
Metabolic activation has-notbeenuniformly achieved in the
prescreens available at this time. In some cases the metabolic
capabilities ofthecells, organs, ororganisms arenotcharacter-
ized. Whether a mammalian liver-derived 9000g supernatant
(S-9) fractionormicrosomes fromcellsthatareknowntohave
metaboliccapability isthemostappropriate sourceofexogenous
metabolicactivity isatopicforfurtherresearch. Wouldametab-
olizingsystembeneededonlyforcompoundsshowingnoactivi-
ty inassays?
The criteria for interpreting the results of prescreens are
specificforeachtest, butthereappeartobenouniversalcriteria
for interpreting the results ofin vitro tests. The minimal study
designneedstobeestablishedpriortoanyvalidationstudy. What
will constitute a positive or negative effect? What is the con-
fidence in apositive or(especially) negative outcome?
Theendpointconcordance(definedastheabilitytorecapitu-
latein vivodataforeitherdevelopmental toxicantsornondeve-
lopmental toxicants) and the accuracy (defined as the overall
abilitytoobtainthesameoutcomeasin vivotests)ofinvitrodata
forin vivofindingsisuncertain; concordancemaynotnecessari-
lybearequirementforavalidtest(see"Validation"). Sincecon-
cordance between Segment II results and effects in humans is
variabledepending onthespeciesandtestcompounds, concor-
dance isperhaps a mootpointforprescreens.
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The level oftolerance forfalsepositives orfalsenegatives was
notagreedupon. Thewasnoconsensus abouttheminimumac-
curacy foratesttobeuseful. Theselevels mayvary, depending
on the purpose for whichthe assay is conducted.
Validation
Several speakers agreedthatthereisageneralpathtoassayac-
ceptability. Ingeneral, itisnecessarytodefinethemodelandits
significance (and limitations), characterize the test system, and
conduct studies with a limited number ofcompounds. This is
followed by an evaluationofthe developed test, with intra- and
interlaboratory standardization and testing with a largernumber
of coded compounds. Validated tests have broad acceptance,
potential credibility forregulatory purposes, andhavebeenused
to test many agents. Studies to understand the scientific nature
ofthe tests may be ongoing during any or all ofthese stages of
validation.
Some prescreens havebeendeveloped to an extent where they
warrant further validation. None of the prescreens was con-
sidered fully validated forbroad prescreening purposesofcom-
pounds withunknown developmental toxicity. Someprescreens
are sufficiently promising that they definitely warrant further
validation efforts.
Development and refinement of systems for investigation of
mechanisms oftoxicity will take its own course. Theexploration
of systems for mechanistic research is independent of the
validation considerations thatwouldbeimposed ontests used as
prescreens.
There was noagreement reached aboutthecriteria forand the
approach to validation. If a prescreen is based on a highly
specific mechanistic event, the factthatthe event ismeasured in
that test was considered to be sufficient validation by some in-
vestigators. Others considered that any prescreen must be able
toproperly distinguishbetween chemicals thatareknowntopro-
ducedevelopmental toxicity and those that lack such properties
andtodistinguish selective embryotoxicity from generaltoxicity
to be considered valid. Relevant concentrations and end points
should be used.
It was generally agreed that testing protocols must be stand-
ardized to conduct validation studies. Further, it was suggested
that investigators test compounds without knowledge of their
identity andthatoutcomes bedecidedpriortodecoding thedata.
The evaluation criteria must be clearly stated before the vali-
dation study is initiated. Interlaboratory concordance is essen-
tial; the assay must produce equivalent results in independent
laboratories.
FutureEfforts and Considerations
Consideration should be given to a validation approach of
parallel testing with prescreens as chemicals are tested in Seg-
mentII studies. Asorganizations test specific chemicals in Seg-
ment II developmental toxicity screens, they should consider
simultaneously testing the same substances in in vitro tests as
prescreens to compare the outcome with that of Segment II
studies. Publishing such comparisons would vastlyexpedite the
evaluation ofthese tests, especially ifindustry-widecoordination
was achieved.
Perhapsthe mostcommonly agreeduponpointofthewhole
workshop was the need for a new reference list ofpositive and
negative agents as regards mammalian developmental toxicity.
There was agreement that a new list was desirable; the chief
criticism ofthe only published list (3), which has become the
basis for preliminary validations, was that the assessment of
maternal toxicity was not complete according to present day
standards. It was pointed out that several known human tera-
togens actonlyatlevelsthatproduceobvious/overtmaternaltoxi-
city. Thus, excessiveconcernovermaternaltoxicity maynotbe
warranted, as it is impossible atthepresenttime toascertain a
causalrelationshipbetweenmaternalanddevelopmentaltoxicity.
Another criticism ofthat and other proposed lists is that there
may be too many chemicals included that act by similar
mechanisms. Theprimarypurposeofanewreferencelistwould
betohelpfocusfurthervalidationeffortsandresearchtodevelop
new test systems. Criteria mustbeestablished suchthatchem-
icals included onthe list would permit arigorous evaluation of
anyprescreeninsubsequentvalidationstudies. Avarietyofcom-
pounds shouldbeconsideredforthelist, representinggradations
ofdevelopmental toxicity. Criteria forselection ofchemicals for
the referencelistmightinclude, butnotnecessarilybelimited to:
a)the weightofevidence foreffects inanimals andhumans, b)
themechanismoftoxicity, chemicalstructure/function/class, c)
theadulttodevelopmental toxicity (A/D) ratioindevelopmental
toxicity studies, andd)the selectionofchemicals thatarestruc-
turally and configurationally closely related (e.g., enantiomers)
known to be either positive or negative in in vivo screens.
Random selection fromtheuniverse ofchemicals was notonly
considered unnecessary butprobably inadvisable. Selection for
and inclusiononthe list mustalsotakeintoaccountthecostand
avilability ofthe chemicals as well asthe ability to work safely
with the substance in the laboratory.
An expert group should be asked to develop such a list, and
consideration should be given to designating a subset ofcom-
pounds that might be used as a short list toquickly evaluate the
potential ofaprescreen to produce results in concordance with
the reference chemicals ofestablished developmental toxicity.
Concordanceoftestoutcomewiththeshortlistmaythenbeused
as acriterion to proceed with full-scale validation. There wasa
suggestion thathuman developmental toxicants maybe useful as
positivecompounds onashortlist. Graphicalactivity profiles for
developmental toxicity end pointdescribed at theworkshop (4)
may be very useful in summarizing data for many compounds.
Experience fromgenetic toxicology validation studiesdesign-
edtopredicttheoutcomeofcarcinogenicity bioassays leadsone
to believe that adding additional assays (i.e., creating abattery
oftests) maynotimprovepredictive ability ofshort-term assays
and may raise costs to unacceptable levels that are not com-
petitive with conventional in vivo screening. Based on the ex-
perience ingenetic toxicology, it is clear that validation studies
mustbewell designedandmanaged. Itisdesirable to standardize
the protocol, use random chemical selection from a reference
list, includedevelopmental/nondevelopmental toxicants, do the
testing blind, conduct intra- and interlaboratory comparisons,
andanalyze theresulting datauniformly andobjectively. Itisbest
toknow themechanistic linkto invivoresults, to understand the
test's role (confirmatory, part of a battery, etc.), statistical
methods, and minimal criteria (number of doses, conditions,
267268 SCHWE7ZETAL.
durationofexposure, etc.). Ifanegativeresultwillnothavethe
sameimpactasapositiveone, thenthereisreasontoquestionthe
rationale fortheentireprescreening approach.
Itisnecessary toconsidertherouteofexposureandotherfac-
tors thatmayinfluencedevelopmental toxicity, e.g., formalde-
hyde injected into conceptuses in utero may produce very dif-
ferent effects than when entering thebody by ingestion. Thus,
pharmacokinetics in viomayprovideguidancefortherelevance
ofin vitro concentrations.
Summary and Recommendations
Participants in theworkshop demonstrated considerable en-
thusiasm for further development andvalidation ofshort-term
and in vitro prescreens both fordevelopmental toxicity testing
andasexperimental systemstoexploremechanismsofactionof
toxicants. Factors thatwereconsideredimportantforfuturead-
vances inthis field include: a) development ofa new reference
list. ThelistproposedbySmithetal. (3)needstobeupdatedac-
cording tocurrently availabledata. Thelistneedstobeexpanded
ormodifiedaccordingtoselectioncriteriawhichmustbeagreed
upon by a knowledgeable review panel. b) An expert group
should further evaluate performance requirements for a pre-
screen to be considered validated. This group should define
whatkindofperformance (concordance)criteriaareconsidered
minimal performance for an assay. c) The role for in vitro
teratology prescreening systemsmustbeclearlydefined (either
forproductdevelopment, regulatoryuse, ormechanistic studies).
d) Too few in vitro teratology prescreens have been evaluated
undermultiple-laboratorytrialswithcommon, agreed-upontest
agentstodrawfirmconclusionsregardingthereproducibilityof
invitroteratologyprescreens. Thereisaneedtomoveseveralof
theseassays furtheralongthevalidationpathway, atleastusing
a short listofreference compounds.
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